Literature DB >> 29689427

Multicentre study evaluating matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically isolated Elizabethkingia species and analysis of antimicrobial susceptibility.

Y-H Cheng3, C-L Perng2, M-J Jian1, Y-H Cheng3, S-Y Lee4, J-R Sun5, H-S Shang6.   

Abstract

OBJECTIVES: Rapid identification of Elizabethkingia species is essential because these species show variations in antibiotic susceptibility and clinical outcomes. Many recent inaccuracies in Elizabethkingia identification by matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) have been noted. Accordingly, in this study, we evaluated the use of MALDI-TOF MS with an amended database to identify isolates of Elizabethkingia anophelis, E. miricola and E. meningoseptica. We then investigated the antimicrobial susceptibility of Elizabethkingia.
METHODS: MALDI-TOF MS spectra were acquired from formic acid extracts overlaid with α-cyano-4-hydroxycinnamic acid matrix on target slides in linear positive ion mode for m/z 2000 to 20 000 Da. Spectra were analysed and SuperSpectra were created with SARAMIS premium software. 16S rRNA gene sequencing was used as the reference standard for species identification. Antibiotic susceptibility was assessed by broth microdilution.
RESULTS: A total of 103 E. anophelis, 21 E. miricola and 11 E. meningoseptica isolates were used to calculate the average spectra and exclude common peaks. SuperSpectra were added to the SARAMIS taxonomy database; all validation results were correct, even for isolates not included in SuperSpectra. Confirmation by direct colony formation was also performed. Overall, the positive predictive value of SuperSpectra was 100% for all isolates. E. miricola (77%, 17/22) was more susceptible to levofloxacin than E. anophelis (16%, 17/105). Doxycycline and minocycline were effective against all Elizabethkingia species.
CONCLUSIONS: Spectral analysis software identified significant species-specific peaks to create reference masses for efficient and accurate identification of Elizabethkingia species, providing accurate information for clinical treatment of Elizabethkingia infections.
Copyright © 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antimicrobial; Broth microdilution; Elizabethkingia; MALDI-TOF MS; SARAMIS database; SuperSpectra; VITEK MS

Mesh:

Substances:

Year:  2018        PMID: 29689427     DOI: 10.1016/j.cmi.2018.04.015

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  10 in total

1.  In vitro activities of imipenem, vancomycin, and rifampicin against clinical Elizabethkingia species producing BlaB and GOB metallo-beta-lactamases.

Authors:  Tein-Yao Chang; Hsing-Yu Chen; Yu-Ching Chou; Yun-Hsiang Cheng; Jun-Ren Sun
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2019-07-27       Impact factor: 3.267

2.  Antimicrobial Susceptibility of Elizabethkingia Species: Report from a Reference Laboratory.

Authors:  Isin Y Comba; Audrey N Schuetz; Anisha Misra; Daniel Z P Friedman; Ryan Stevens; Robin Patel; Zane D Lancaster; Aditya Shah
Journal:  J Clin Microbiol       Date:  2022-05-05       Impact factor: 11.677

3.  Isolation and Characterization of a New Phage Infecting Elizabethkingia anophelis and Evaluation of Its Therapeutic Efficacy in vitro and in vivo.

Authors:  Shih-Yi Peng; Li-Kuang Chen; Wen-Jui Wu; Prajna Paramita; Po-Wei Yang; Yun-Zhong Li; Meng-Jiun Lai; Kai-Chih Chang
Journal:  Front Microbiol       Date:  2020-05-13       Impact factor: 5.640

Review 4.  Elizabethkingia Infections in Humans: From Genomics to Clinics.

Authors:  Jiun-Nong Lin; Chung-Hsu Lai; Chih-Hui Yang; Yi-Han Huang
Journal:  Microorganisms       Date:  2019-08-28

5.  MBLs, Rather Than Efflux Pumps, Led to Carbapenem Resistance in Fosfomycin and Aztreonam/Avibactam Resistant Elizabethkingia anophelis.

Authors:  Yanbin Chang; Daiqin Zhang; Siqiang Niu; Qian Chen; Qiuxia Lin; Xiaobing Zhang
Journal:  Infect Drug Resist       Date:  2021-01-29       Impact factor: 4.003

6.  Comparative Analysis of Gradient Diffusion and Disk Diffusion with Agar Dilution for Susceptibility Testing of Elizabethkingia anophelis.

Authors:  Chien-Tung Chiu; Chung-Hsu Lai; Yi-Han Huang; Chih-Hui Yang; Jiun-Nong Lin
Journal:  Antibiotics (Basel)       Date:  2021-04-16

7.  Epidemiological, clinical, and laboratory features of patients infected with Elizabethkingia meningoseptica at a tertiary hospital in Hefei City, China.

Authors:  Yajuan Li; Tingting Liu; Cuixiao Shi; Bo Wang; Tingting Li; Ying Huang; Yuanhong Xu; Ling Tang
Journal:  Front Public Health       Date:  2022-09-20

8.  Molecular typing and profiling of topoisomerase mutations causing resistance to ciprofloxacin and levofloxacin in Elizabethkingia species.

Authors:  Ming-Jr Jian; Yun-Hsiang Cheng; Cherng-Lih Perng; Hung-Sheng Shang
Journal:  PeerJ       Date:  2018-09-12       Impact factor: 2.984

9.  Joint infection due to Elizabethkingia miricola.

Authors:  E Calatrava; I Casanovas; C Foronda; F Cobo
Journal:  Rev Esp Quimioter       Date:  2020-03-10       Impact factor: 1.553

10.  The Evolutionary Trend and Genomic Features of an Emerging Lineage of Elizabethkingia anophelis Strains in Taiwan.

Authors:  Yu-Lin Lee; Kuan-Ming Liu; Hui-Lan Chang; Yi-Ci Liao; Jen-Shiou Lin; Fang-Yen Kung; Cheng-Mao Ho; Kai-Hsiang Lin; Ying-Tsong Chen
Journal:  Microbiol Spectr       Date:  2022-01-19
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.